Pages

▼
Showing posts with label MERCK. Show all posts
Showing posts with label MERCK. Show all posts

Merck Acquires IOmet Pharma

›
Merck announced that it has acquired IOmet, a privately-held UK-based drug discovery company focused on the development of innovativ...

FDA Approves Expanded Indication of KEYTRUDA in Melanoma

›
Merck announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for KEYTRUDA ® (pembrolizumab),...

FDA Approves Expanded Age Indication for GARDASIL 9 in Males

›
Merck announced that the U.S. Food and Drug Administration (FDA) approved an expanded age indication for GARDASIL ® 9 (Human Papillomavirus...

Merck Decides Not to Pursue Evofosfamide

›
Merck    announced that it is not planning to file for approval of evofosfamide in advanced soft tissue sarcoma and advanced pancreatic ade...

Merck Statement Regarding CUBICIN Patent Litigation

›
Merck issued the following statement regarding the decision of the U.S. Court of Appeals for the Federal Circuit. The decision valid...

Merck Animal Health to Acquire Harrisvaccines

›
Merck Animal Health and Harrisvaccines, Inc., announced the companies have entered into an agreement under which Merck Animal Health will...

Glucophage® XR Can be Used for Type 2 Diabetes Patients

›
Merck, a leading science and technology company, announced that the British Medicines and Healthcare products Regulatory Agency (MHRA), h...

Merck Receives Breakthrough Therapy Designation from USFDA

›
Merck announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KEYTRUDA ® ...

New Findings Show Anti-Tumor Activity of KEYTRUDA

›
Merck  announced the first-time presentation of findings investigating the use of KEYTRUDA ®  (pembrolizumab), the company’s anti-PD-1 ther...

FDA Approves Pediatric Indication for EMEND Capsules

›
Merck announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for EMEND ® ...